| Biomarker ID | 1326 |
| PMID | 24486077 |
| Year | 2014 |
| Biomarker | Monoclonal Antibody MIB-1 [Ki-67] |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Increased with increased risk of death |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.10 (95% CI: 1.07-1.13) |
| Effect on Pathways | Pathways Include: DNA Damage; Neuroscience; Primary Focal Segmental Glomerulosclerosis FSGS |
| Experiment | Progression Vs No Progression |
| Type of Biomarker | Prognostic |
| Cohort | 451 patients with Radical Prosteactomy out of which 46 experienced progression and 18 died of prostate cancer were included in the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |